STD rates in the U.S. hit a new high for the 6th straight year
State of the Art STI Pathogen Detection
The Absolute Genomics STI InSITE Panel is an RT-PCR test -based assay with a proven track record of high specificity and sensitivity. Traditional methods involving culturing and microscopy are time consuming and have lower accuracy / sensitivity. The Panel is a faster and more reliable solution for detecting bacterial vaginosis, Chlamydia, Gonorrhea, Trichomoniasis and other sexually transmitted infections. The STI InSITE Panel has 13 pathogen targets which were selected based on epidemiological data and feedback from our client pool. This technique allows Absolute Genomics to process an increased number of samples per instrument per day with turnaround times under 24 hours. All bacterial targets if detected are subsequently tested for antibiotic resistance markers and the information provided in Arkstone Antimicrobial Resistance Report that provides the best treatment option for detected pathogens.
Clinical Need :
- 1 in 5 people in the US have an STI
- Almost half of new STIs are among youth aged 15-24 in the US
- New STIs total nearly $16 billion in direct medical costs
- Traditional testing methods like gram staining have a ~3% failure rate
- ~21 million women get bacterial vaginosis between the age of 14-49 in the U.S.
- Vaginal candidiasis caused by candida species or other yeasts effects 75% of women at least once in their lifetime
- ~40-45% of women get vaginal candidiasis at least 2 times in their lifetime
- Patients with co-infections depend on accurate and timely diagnosis to be treated in time
- Major advantages of the PCR technique are higher accuracy, quicker turnaround time, and a comprehensive report
~2.5 million Americans suffer from STD infections annually
ABx Advantage
The Absolute Genomics ABx Advantage gene panel is designed to detect major classes of antibiotic resistance. This panel can identify the presence of specific resistance genes that are involved in drug inhibition. The Absolute Genomics ABx Advantage gene panel has 11 antibiotic resistance genes belonging to amino glycosidea β-lactama fluoroquinolonea macrolidea tetracyclinea vancomycina and multi-drug resistance classifications. The data is used for providing antibiotic resistance stewardship via Arkstone Medical Solutions. The OneChoice report powered by Arkstone Medical Solutions for the ABx Advantage gene panel converts PCR data into simple interpretations for physicians to help them make better treatment decisions. This technology is a combination of softwarea artificial intelligencea and human expertise.
- The antimicrobial report contains a unique ArkScore to help prescribers make informed decisions.
- The antimicrobial decision engine combines machine-learning artificial intelligence with decades of deep infectious disease expertise to guide physicians to a singular treatment regimen that targets the most relevant infection with the lowest risk to the patient.
- ArkScore describes the level of antimicrobial resistance expressed in organisms.
- ArkScore provides the most effective treatment with the least risk of adverse events resulting in the reduction of unnecessary use of broad-spectrum antibiotics
Extensive Panel List
Bacteria
- Atopobium vaginae
- BVAB2
- Chlamydia trachomatis
- Neisseria gonorrhoeae
- Gardnerella vaginalis
- Haemophilus ducreyi
- Mobiluncus curtisii
- Mobiluncus mulieris
- Mycoplasma genitalium
- Mycoplasma hominis
Fungi
- Candida albicans
- Candida parapsilosis
- Candida krusei
- Candida lusitaniae
- Candida tropicalis
- Candida glabrata
Parasite
- Trichomonas vaginalis
Viruses
- HSV1
- HSV2
lorem ipsum Panel List
- XYZ
- XYZ
- XYZ
- XYZ
- XYZ
- XYZ
- XYZ
- XYZ
- XYZ
- XYZ
- XYZ
- XYZ
